Table 3.

Clinical Outcomes, Costs, and Incremental Cost-Effectiveness Ratios for Screening Strategies for 10,000 Patients with CoA

Screening Strategy	Prophylactic Treatment*†			SAH*			LE	QALY‡	Cost‡	ICER
	All	Death	MC	All	Death	MC	(yr)	(yr)	($)	($/QALY)
No Screen	0	0	0	1013	183	272	57.86	24.212	90	Reference
Age 10	381	8	61	729	132	197	57.99	24.246	1,617	45,921
Age 10, 20	701	14	107	515	94	140	58.06	24.260	2,562	65,243
Age 10, 20, 30	978	19	144	353	65	96	58.08	24.266	3,157	106,841
Age 10, 20, 30, 40	1203	23	171	244	45	67	58.10	24.267	3,513	265,764

MC = major complication (death or permanent disability); SAH = subarachnoid hemorrhage; LE = life expectancy; yr = year; ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life expectancy

^*Number experiencing the outcome in a population of 10,000 patients with CoA

^†Only initial treatment, excludes re-treatment

^‡QALYs and costs discounted at 3% per year